がん治療法の世界市場:用途別、人気商品別...市場調査レポートについてご紹介

【英文タイトル】Cancer Therapeutics Market by Application (Blood Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Glioblastoma, Malignant Meningioma, Mesothelioma, Melanoma, and Others) and Top Selling Drugs (Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Market share analysis, 2018
3.4. Porters five forces analysis
3.5. Clinical trials
3.6. Market dynamics

3.6.1. Drivers

3.6.1.1. Increase in prevalence of cancer
3.6.1.2. Surge in cancer research
3.6.1.3. Rise in strategic acquisitions & collaborations

3.6.2. Restraints

3.6.2.1. High cost of drug development and threat of failure
3.6.2.2. Adverse effects associated with cancer drug therapy

3.6.3. Opportunities

3.6.3.1. High potential associated with personalized medicines
3.6.3.2. Increase in purchasing power of emerging economies

CHAPTER 4: CANCER THERAPEUTICS MARKET, APPLICATION

4.1. Overview

4.1.1. Market size and forecast

4.2. Blood cancer

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Lung cancer

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Breast cancer

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Colorectal cancer

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

4.6. Prostate cancer

4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

4.7. Cervical cancer

4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country

4.8. Head & neck cancer

4.8.1. Key market trends, growth factors, and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country

4.9. Glioblastoma

4.9.1. Key market trends, growth factors, and opportunities
4.9.2. Market size and forecast, by region
4.9.3. Market analysis, by country

4.10. Malignant meningioma

4.10.1. Key market trends, growth factors, and opportunities
4.10.2. Market size and forecast, by region
4.10.3. Market analysis, by country

4.11. Mesothelioma

4.11.1. Key market trends, growth factors, and opportunities
4.11.2. Market size and forecast, by region
4.11.3. Market analysis, by country

4.12. Melanoma

4.12.1. Key market trends, growth factors, and opportunities
4.12.2. Market size and forecast, by region
4.12.3. Market analysis, by country

4.13. Others

4.13.1. Key market trends, growth factors, and opportunities
4.13.2. Market size and forecast, by region
4.13.3. Market analysis, by country

CHAPTER 5: CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS

5.1. Overview

5.1.1. Market size and forecast

5.2. Revlimid

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by region

5.3. Avastin

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by region

5.4. Herceptin

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by region

5.5. Rituxan

5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by region

5.6. Opdivo

5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by region

5.7. Gleevec

5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by region

5.8. Velcade

5.8.1. Market size and forecast, by region
5.8.2. Market analysis, by region

5.9. Imbruvica

5.9.1. Market size and forecast, by region
5.9.2. Market analysis, by region

5.10. Ibrance

5.10.1. Market size and forecast, by region
5.10.2. Market analysis, by region

5.11. Zytiga

5.11.1. Market size and forecast, by region
5.11.2. Market analysis, by region

5.12. Alimta

5.12.1. Market size and forecast, by region
5.12.2. Market analysis, by region

5.13. Xtandi

5.13.1. Market size and forecast, by region
5.13.2. Market analysis, by region

5.14. Tarceva

5.14.1. Market size and forecast, by region
5.14.2. Market analysis, by region

5.15. Perjeta

5.15.1. Market size and forecast, by region
5.15.2. Market analysis, by region

5.16. Temodar

5.16.1. Market size and forecast, by region
5.16.2. Market analysis, by region

5.17. Other drugs

5.17.1. Market size and forecast, by region
5.17.2. Market analysis, by region

CHAPTER 6: CANCER THERAPEUTICS MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country

6.2.2.1. U.S.

6.2.2.1.1. U.S. market size and forecast, by application

6.2.2.2. Canada

6.2.2.2.1. Canada market size and forecast, by application

6.2.3. North America market size and forecast, by application
6.2.4. North America market size and forecast, by top selling drugs

6.3. Europe

6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe cancer therapeutics market, by country

6.3.2.1. Germany

6.3.2.1.1. Germany market size and forecast, by application

6.3.2.2. France

6.3.2.2.1. France market size and forecast, by application

6.3.2.3. UK

6.3.2.3.1. UK market size and forecast, by application

6.3.2.4. Italy

6.3.2.4.1. Italy market size and forecast, by application

6.3.2.5. Spain

6.3.2.5.1. Spain market size and forecast, by application

6.3.2.6. Rest of Europe

6.3.2.6.1. Rest of Europe market size and forecast, by application

6.3.3. Europe market size and forecast, by application
6.3.4. Europe market size and forecast, by top selling drugs

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country

6.4.2.1. Japan

6.4.2.1.1. Japan market size and forecast, by application

6.4.2.2. China

6.4.2.2.1. China market size and forecast, by application

6.4.2.3. India

6.4.2.3.1. India market size and forecast, by application

6.4.2.4. Taiwan

6.4.2.4.1. Taiwan market size and forecast, by application

6.4.2.5. South Korea

6.4.2.5.1. South Korea market size and forecast, by application

6.4.2.6. Australia

6.4.2.6.1. Australia market size and forecast, by application

6.4.2.7. Rest of Asia-Pacific

6.4.2.7.1. Rest of Asia-Pacific market size and forecast, by application

6.4.3. Asia-Pacific market size and forecast, by application
6.4.4. Asia-Pacific market size and forecast, by top selling drugs

6.5. LAMEA

6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA market size and forecast, by country

6.5.2.1. Latin America

6.5.2.1.1. Latin America market size and forecast, by application

6.5.2.2. Middle East

6.5.2.2.1. Middle East market size and forecast, by application

6.5.2.3. Africa

6.5.2.3.1. Africa market size and forecast, by application

6.5.3. LAMEA market size and forecast, by application
6.5.4. LAMEA market size and forecast, by top selling drugs

CHAPTER 7: COMPANY PROFILES

7.1. AbbVie Inc.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. Astellas Pharma Inc.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. Bristol Myers Squibb Company

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments

7.4. Celgene Corporation

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. Eli Lilly and Company

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. F. Hoffmann-La Roche Ltd.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. EleInformatiBusiness performance
7.6.6. Key strategic moves and developments

7.7. Johnson & Johnson

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. Merck & Co., Inc.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments

7.9. Novartis AG

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments

7.10. Pfizer Inc.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments


【レポート販売概要】

■ タイトル:がん治療法の世界市場:用途別、人気商品別
■ 英文:Cancer Therapeutics Market by Application (Blood Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Glioblastoma, Malignant Meningioma, Mesothelioma, Melanoma, and Others) and Top Selling Drugs (Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026
■ 発行日:2019年7月
■ 調査会社:Allied Market Research
■ 商品コード:AMR9NV072
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。